CSTM Stock Constellium SE (CSTM, $27.14) Moving Average Convergence Divergence (MACD) Histogram turned positive on September 4, 2026
at Tickeron.com
This is a Bullish indicator signaling CSTM's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 58 similar cases where CSTM's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:
CSTM's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CSTM turned positive on September 04, 2026. Looking at past instances where CSTM's MACD turned positive, the stock continued to rise in 50 of 57 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +3.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where CSTM advanced for three days, in 225 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
CSTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CSTM as a result. In 79 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for CSTM entered a downward trend on August 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.847) is normal, around the industry mean (2.601). CSTM has a moderately low P/E Ratio (6.762) as compared to the industry average of (9.016). CSTM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.014). P/S Ratio (0.384) is also within normal values, averaging (0.904).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. CSTM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.